本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
New clinical evidence highlights a smarter, technology-driven approach to scar management, rejuvenation, and tattoo removal HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced that its core subsidiary, Alma, the Group's Energy-Based Devices (EBD) brand, featured its vision for the future of Intelligent Aesthetics at the IMCAS World Congress in Paris, held from 29 to 31 January 2026, highlighting its commitment to empowering practitioners with personalized, evidence-based solutions that elevate patient care and advance modern aesthetic practice. As a core contributor to the IMCAS scientific programme, Sisram presented new clinical data and case studies demonstrating its continued leadership in intelligent, energy-based aesthetic solutions. The presentations highlighted Alma's innovative value of multi-technology laser platforms across a range of applications, including advanced laser-based rejuvenation as a foundational element of modern aesthetic care, as well as the application of multiple wavelengths within a single platform for complex tattoo removal. Together, these findings reinforce Alma's leadership in intelligent energy-based solutions and its commitment to advancing evidence-driven aesthetic practice. During the congress, Alma showcased technological advancements across key applications, including new clinical study findings on the Alma Hybrid platform for managing keloid scars together with surgery and trans-epidermal delivery of steroids. Additional sessions addressed acne and acne-scar management across the clinical spectrum, alongside live demonstrations featuring Harmony Bio-Boost, Alma's award-winning collagen-stimulating rejuvenation treatment. Alma IQ, the Company's advanced skin analysis platform, further demonstrated its ability to support personalized assessments and to assist doctors in developing precise treatment plans from the very first patient interaction. Mr. Eyal Ben David, CEO of Sisram and Alma, said: "IMCAS stands among the most influential scientific platforms shaping the future of medical aesthetics. Our expanded presence this year underscores Alma's commitment to redefining aesthetic care through rigorous clinical evidence and disruptive technological innovation. By advancing precision diagnostics, personalized treatment planning, and integrated care pathways, we are empowering practitioners to deliver superior patient outcomes and transform aesthetics into sustained, long-term patient engagement." Following the scientific programme, Mr. Lior Dayan, Chairman of Sisram, was invited to attend the IMCAS World Congress Economic Forum La Tribune 2026, where he joined global industry leaders to discuss how intelligent technologies and clinical insight are shaping the future landscape of medical aesthetics. About Sisram Medical Ltd Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD). Built on a legacy of innovation and clinical excellence, the Company's synergistic ecosystem spans EBD technologies, injectables, diagnostics, and complementary solutions. Serving customers in over 110 countries and regions, Sisram delivers award-winning products that set new standards in safety, efficacy, and personalized aesthetic care for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017. For more information, please visit: https://sisram-medical.com/.
SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO: Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial in the United States. Members of the PharmaResearch PRD-101 Project Team PRD-101 is a next-generation nano anticancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT® (DNA Optimizing Technology). The drug leverages the company's nucleotide-based Advanced DOT™ drug delivery platform, designed to enable efficient loading of therapeutics and improve pharmacokinetics. The Phase 1 clinical trial will be conducted across up to seven clinical sites in the United States and is expected to enroll approximately 90 patients with locally advanced or metastatic solid tumors. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of PRD-101. "The FDA clearance of our IND application marks an important milestone for PRD-101. Through this Phase 1 trial, we aim to further characterize PRD-101 and continue advancing our oncology pipeline," PharmaResearch stated. About PharmaResearch's PRD-101 PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch's proprietary DNA optimizing technology (DOT®) in nanoparticle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive licenses associated with PRD-101, marking a milestone in the company's innovative endeavors. Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy. About PharmaResearch PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life through regenerative medicine. With a diverse portfolio that includes medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients—DOT® PDRN and DOT ® PN—which are protected by a suite of patents. Headquartered in Gangneung-si, Gangwon-do, South Korea, PharmaResearch also has a subsidiary in Costa Mesa, California. For more information about PharmaResearch, visit https://pharmaresearch.com/en
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY® (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. As a next-generation selective S1P receptor modulator, VELSIPITY® offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC. The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12). The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY® or placebo. The study results showed that, VELSIPITY® demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY® was consistent with previous studies, with no new safety signals observed. ELEVATE UC 52 and ELEVATE UC 12 are randomized, double-blind, placebo-controlled global phase 3 pivotal studies, which further demonstrate the positive benefit-risk profile of VELSIPITY®. "Autoimmune diseases have long-term impacts on patients worldwide, with significant unmet clinical needs persisting both in China and globally, "said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "The approval of VELSIPITY® underscores the clinical value of innovative therapies for UC and reflects Everest Medicines' sustained commitment to advancing drug development in line with international R&D standards. We look forward to expanding our global reach and providing patients with broader access to innovative treatment options." "Ulcerative colitis is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system," said Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University. "Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse risk, and supports long-term disease management. As a next-generation selective S1P receptor modulator, VELSIPITY® is a once-daily oral therapy with rapid onset of action, strong mucosal healing efficacy, and a favorable safety profile, offering a new long-term treatment option for adults with moderately to severely active UC." "UC treatment in China has long faced limited efficacy, high relapse rates, safety concerns, and inconvenient dosing. Despite available biologics and small-molecule therapies, unmet clinical needs persist," said Prof. Wu Kaichun of the First Affiliated Hospital of AFMU, principal investigator of VELSIPITY®'s Asian clinical trial. "Results from the ENLIGHT UC study demonstrated that the clinical remission rate at week 40 of the maintenance period reached 48.1%, and the deep mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%[1]. As the first Phase 3 registrational study in Asian patients with moderately to severely active UC, the study confirms the efficacy and safety of VELSIPITY® in this population, with results published in The Lancet Gastroenterology & Hepatology[1]. Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management." UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031[2],[3]. Symptoms include mucous and bloody stools, abdominal pain, diarrhea and rectal tenesmus, all of which significantly impact patients' long-term quality of life. There remains a critical need for therapies that offer sustained and comprehensive disease control. "In China, a large population of patients with moderately to severely active UC continues to face substantial unmet medical needs," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "VELSIPITY® provides patients with moderately to severely active ulcerative colitis a once-daily oral therapy with the potential to achieve steroid-free remission and a favorable benefit–risk profile. Its approval in China addresses a critical unmet medical need and introduces a novel oral therapy promoting deep mucosal healing. We are committed to rapidly commercializing VELSIPITY® and working toward its inclusion in the National Reimbursement Drug List to further expand patient access and affordability, benefiting more patients across China." The clinical value of VELSIPITY® has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY® was also included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, with strong recommendations supporting its use for both induction and maintenance of remission in patients with moderately to severely active UC. In 2024, VELSIPITY® was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. The localized production project for VELSIPITY® was launched at the Jiashan manufacturing site in March 2025, supporting its future commercialization in China. About VELSIPITY® (etrasimod arginine tablets) VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds to S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Japan, Australia, Singapore, UK, Switzerland, Israel, Turkey, India, Hong Kong SAR, Macao SAR and Mainland China for VELSIPITY® in ulcerative colitis, as well as in additional countries. About Phase 3 ENLIGHT UC Registrational study (ES101002) ENLIGHT is the largest Phase III trial of moderately to severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to receive etrasimod or placebo. Patients with an inadequate response or intolerance to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy were randomized to receive etrasimod once-daily or placebo for 12 weeks of induction treatment. Patients who completed the 12-week induction period and responded were re-randomized into the 40-week maintenance period to receive once-daily etrasimod or placebo. The primary efficacy endpoints were the proportion of patients achieving clinical remission at Week 12 (induction) and Week 40 (maintenance). The key secondary endpoints of the study were the proportion of patients achieving endoscopic improvement and clinical response at Week 12 (induction) and at Week 40 (maintenance). The study results showed that, during both the 12-week induction phase and the 40-week maintenance phase, etrasimod demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints. A significantly greater proportion of patients treated with etrasimod than those treated with placebo achieved clinical remission at induction Week 12 (57 [25.0%] of 228 patients vs 6 [5.4%] of 112 patients; adjusted difference 20.4%, 95% CI 13.4–27.4, p<0.0001) and at maintenance Week 40 (37 [48.1%] of 77 patients vs 10 [12.5%] of 80 patients; adjusted difference 35.9%, 95% CI 22.5–49.2, p<0.0001). At induction Week 12, a significantly greater proportion of patients treated with etrasimod than those treated with placebo showed endoscopic improvement (85 [37.3%] of 228 patients treated with etrasimod vs 11 [9.8%] of 112 patients treated with placebo; adjusted difference 28.6%, 95% CI 20.5–36.7, p<0·0001) and clinical response (133 [58.3%] of 228 patients treated with etrasimod vs 31 [27.7%] of 112 patients treated with placebo; adjusted difference 32.0%, 95% CI 21.8–42.2, p<0·0001). At maintenance Week 40, a significantly greater proportion of patients treated with etrasimod than those treated with placebo showed endoscopic improvement (47 [61.0%] of 77 patients treated with etrasimod vs 12 [15.0%] of 80 patients treated with placebo; adjusted difference 46.6%, 95% CI 33.2–60.1, p<0·0001) and clinical response (61 [79.2%] of 77 patients treated with etrasimod vs 28 [35.0%] of 80 patients treated with placebo; adjusted difference 45.6%, 95% CI 31.9–59.3, p<0·0001). Other secondary endpoints, including mucosal healing, endoscopic normalization, and histological remission, also significantly favored patients treated with etrasimod compared with placebo. Notably, mucosal healing as measured by a central read endoscopic subscore≤ 1 (excluding friability) with a Geboes Index score < 2.0, was achieved in 51.9% of the etrasimod treated patients compared to 8.8% in the placebo group (p<0.0001). The safety profile of etrasimod during the maintenance period was consistent with previous studies, with no new safety findings observed. About ELEVATE UC Phase 3 Registrational Program (ELEVATE UC 52 and ELEVATE UC 12) ELEVATE UC 52 and ELEVATE UC 12 are pivotal trials that are part of the ELEVATE UC Phase 3 registrational program[4]. ELEVATE UC 52 is a randomized, double-blind, placebo-controlled trial that utilized a treat-through design comprising a 12-week induction period followed by a 40-week maintenance period. Subjects were randomized to receive etrasimod or placebo and continued on treatment without re-randomization for the entire duration of the study. Beginning at Week 12, all patients could continue their randomized treatment; patients whose disease had not improved or had worsened compared with baseline could discontinue treatment and, if eligible, enroll in an open-label extension study. The primary objective of this trial was to assess the safety and efficacy of etrasimod 2 mg once daily on clinical remission after both 12 and 52 weeks. The primary endpoint was based on the 3-domain, modified Mayo score (MMS). In ELEVATE UC 52, clinical remission was achieved by 27.0% of patients receiving etrasimod compared with 7.0% of patients receiving placebo at Week 12 (19.8% differential, P˂0.0001) and by 32.0% compared with 7.0% at Week 52 (25.4% differential, P˂0.0001). Statistically significant improvements were observed in all key secondary endpoints, including endoscopic improvement and mucosal healing at Weeks 12 and 52, and corticosteroid-free remission and sustained clinical remission at Week 52. ELEVATE UC 12 is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of etrasimod 2 mg once daily in subjects with moderately to severely active UC. The primary objective of this trial was to assess the safety and efficacy of etrasimod on clinical remission at Week 12, as assessed by the 3-domain MMS. In ELEVATE UC 12, clinical remission was achieved among 25.0% of patients receiving etrasimod compared with 15.0% of patients receiving placebo (9.7% differential, P=0.026). All key secondary endpoints were met at Week 12, including endoscopic improvement and mucosal healing. In ELEVATE UC 12, a similar proportion of patients experienced treatment-emergent adverse events (AEs) between the etrasimod 2 mg and placebo treatment groups, while in ELEVATE UC 52, the proportion of adverse events was higher in the etrasimod 2 mg group compared with placebo. The proportion of patients experiencing serious AEs was similar between treatment groups in both trials. The most common treatment-emergent AEs occurring in 3% or more of etrasimod-treated patients and at a higher frequency than placebo through Week 52 in either trial were headache, elevated liver tests, worsening of UC, COVID-19 infection, dizziness, pyrexia, arthralgia, abdominal pain and nausea. Data support that initiation of etrasimod treatment does not require a complex up-titration regimen. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12, respectively, were naïve to biologic or JAK inhibitor therapy. References: [1]. K. Wu, et al. Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198-0. Full results of the ENLIGHT UC study (ES101002) by The Lancet Gastroenterology & Hepatology. [2]. Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679. [3]. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727. [4]. Sandborn WJ, et al. Lancet. 2023 Apr 8;401(10383):1159-1171. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This latest designation applies to ivonescimab in combination with chemotherapy for the first-line treatment of advanced biliary tract cancer (BTC). This milestone represents the fifth BTD awarded to ivonescimab by the NMPA, following three prior designations in lung cancer indications and one for triple-negative breast cancer (TNBC). The repeated recognition highlights ivonescimab's broad clinical potential across multiple high unmet need tumor types. A randomized, controlled, multicenter, registrational Phase III clinical study (AK112-309/HARMONi-GI1) is evaluating ivonescimab plus chemotherapy versus durvalumab (a PD-L1 inhibitor) plus chemotherapy for first-line treatment of advanced BTC. Patient enrollment has been completed, and the BTD status for this indication underscores the promising clinical profile of ivonescimab. The BTD status is expected to accelerate both the ongoing clinical development and the regulatory review process in China. Encouraging results from a Phase 1b/II study, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual meeting, support the potential of the ivonescimab combination therapy as a superior first-line treatment for advanced BTC. In the study, ivonescimab plus chemotherapy achieved an Objective Response Rate (ORR) of 63.6% and a Disease Control Rate (DCR) of 100%. The ivonescimab regimen also demonstrated a median Progression-Free Survival (mPFS) of 8.5 months and a median Overall Survival (mOS) of 16.8 months. These compelling Phase II results provide a robust foundation for the ongoing Phase III registrational trial and reinforce ivonescimab's potential to address the significant unmet needs in advanced BTC, where current treatment options often yield limited durable responses. Forward-Looking Statement of Akeso, Inc.This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About AkesoAkeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin. Akeso Contacts: Media: pr@akesobio.comInvestors: ir@akesobio.com
- Secures distribution agreement to launch CART BP pro in the Japanese hospital and clinic market- Leveraging proven technology with adoptions in 1,700+ medical institutions and national health insurance coverage in Korea SEOUL, South Korea, Feb. 6, 2026 /PRNewswire/ -- Sky Labs Inc. (CEO Jack Byunghwan Lee) announced on the 5th that it has entered into an exclusive distribution agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the ring-type blood pressure monitor, 'CART BP pro', in the Japanese hospital and clinic market. This agreement follows the memorandum of understanding (MoU) signed between the two companies in December 2024. Sky Labs initially explored global expansion opportunities through Korea Otsuka Pharmaceutical, and the introduction by the Korean affiliate led to formal discussions and negotiations with Otsuka's headquarters. Such a collaboration represents a successful open-innovation case in which a Korean venture company leveraged the domestic subsidiary of a multinational corporation as a bridge to establish a partnership with its global headquarters. Otsuka is a global pharmaceutical company providing a wide range of medical solutions worldwide, making it one of the most trusted companies in Japan's healthcare landscape. By partnering with Otsuka and leveraging profound expertise in the cardiovascular field as well as its extensive distribution network, Sky Labs aims to reach a broader patient population and accelerate the adoption of CART BP pro across hospitals and clinics throughout Japan. The number of hypertension patients in Japan is approximately 43 million, of whom an estimated 29% fail to achieve blood pressure control despite receiving treatment, and 33% are believed to be unaware of their condition.[1] Furthermore, as abnormal 24-hour blood pressure patterns and nocturnal hypertension are linked to increased risks of organ damage and cerebrovascular diseases, the clinical importance of 24-hour blood pressure monitoring is growing. Given these clinical requirements and the vast patient population, CART BP pro is expected to significantly contribute to the management of hypertensive patients in Japan, ranging from precise diagnosis and optimal treatment strategy development to systematic assessment of therapeutic effects. CART BP pro has already demonstrated its technological prowess with tangible results in the Korean market. Following medical device approval from the Ministry of Food and Drug Safety (MFDS) in 2023, it gained clinical recognition in 2024 through national health insurance reimbursement approval. Currently, the device is prescribed for 24-hour Ambulatory Blood Pressure Monitoring (ABPM) in over 1,700 medical institutions nationwide, including tertiary hospitals, surpassing 150,000 cumulative prescriptions within just one year since its domestic launch. This proven track record and clinical reliability in actual medical settings served as the key drivers for securing this exclusive distribution agreement. Conventional blood pressure monitors use an air-inflated cuff to apply pressure and temporarily restrict blood flow for measurement. This method frequently causes discomfort and pain during measurement and can disrupt sleep during nighttime monitoring. In contrast, CART BP pro utilizes photoplethysmography (PPG) technology to measure blood pressure without a cuff. This allows patients to measure their blood pressure comfortably during daily activities and sleep, while medical professionals can obtain stable data to provide appropriate treatment plans. Jack Byunghwan Lee, CEO of Sky Labs, stated, "Starting with our entry into Japan, we will continue to validate our unparalleled blood pressure monitoring technology in the global market, while leaping forward as a leader in the global blood pressure monitoring industry." About Sky Labs https://skylabs.io/en/ Founded in September 2015, Sky Labs is a healthcare company that develops and operates "CART", a ring-type medical device and platform for monitoring chronic disease patients. Since the first CART was developed in 2020 for atrial fibrillation monitoring using cardiac signals from optical sensors, the company has expanded its capabilities. In 2023, Sky Labs received medical device approval for "CART BP pro," a ring-type monitor designed for 24-hour blood pressure measurement. In 2024, CART BP pro was recognized by the Health Insurance Review and Assessment Service (HIRA) under the existing medical procedure of '24-hour ambulatory blood pressure monitoring' (reimbursement code 'E6547'), and is currently being prescribed in hospitals and clinics across Korea. Furthermore, in September 2025, the company launched "CART BP," a consumer-grade ring-type blood pressure monitor, which is available through its official online store and various other online channels. About Otsuka www.otsuka.co.jp/en/ Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. Media InquiriesInok Jung inok.jung@skylabs.ioBomi Lee bomi.lee@skylabs.io [1] Source: The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025)
Singapore Office Expands APAC Presence to Seven Locations, Delivering Enhanced Local Expertise and Global Scale BETHESDA, Md., Feb. 6, 2026 /PRNewswire/ -- Precision for Medicine (Precision), a global leader in biomarker-driven clinical research and development, has announced the opening of a new office in Singapore. This strategic expansion strengthens Precision's significant presence across the Asia-Pacific (APAC) region, serving as a crucial hub for enhanced client support and accelerated regional growth. "This expansion, particularly with our new Singapore hub, signifies a major step in deepening our operational capabilities and localized expertise across APAC," said Jing Ping Yeo, Vice President, Clinical Operations. "By expanding in critical markets like Singapore, we're providing our clients with greater assurance on trial oversight and delivery, accelerating site activation and ultimately ensuring more efficient and higher-quality execution of complex, biomarker-driven clinical programs for patients worldwide." Singapore's central location and sophisticated infrastructure make it ideal for growing Precision's regional presence, including Mainland China, Hong Kong, India, South Korea, Taiwan and Australia. Through its expanded footprint, embedded senior leaders and a dedicated team of over 500 employees, Precision underscores its commitment to navigating the complexities of regional drug development and commercialization. For its global partners, APAC expansion solidifies Precision as a single, unified CRO, eliminating the friction and complexity of managing multiple partners while offering streamlined oversight, clearer lines of accountability, and greater assurance regarding the quality and consistency of trial delivery. Conversely, for regional clients, this enhanced capability empowers them to effectively bring their ground-breaking therapies to global development pathways across the U.S. and Europe. The Precision team features oversight from recognized leaders in several regions of APAC, such as Dr. Yeo, who also chairs the Drug Information Association (DIA) Singapore Advisory Committee and the Singapore Clinical Research Professionals Association (SCRP) and serves on the Program Committee for DIA-Asia, and operational capabilities in the region. "The new Singapore office is a strategic pillar in our mission to be the unified partner for precision medicine development, both globally and within the dynamic APAC landscape," said James Cheong, Senior Vice President, APAC. "This strategic hub facilitates the seamless integration of our extensive global expertise with local insights from our regional teams, positioning us to deliver accelerated solutions and deeper support to our clients." "The opening of our Singapore office is a pivotal moment that significantly strengthens Precision's already robust APAC footprint," said Daisy DeWeese-Gatt, President, Clinical Solutions, Precision for Medicine. "By better integrating diverse APAC data and patient populations, we can advance new medicines faster, ensuring therapies are better tailored and more representative of real-world diversity for patients globally with high unmet needs." About Precision for MedicinePrecision for Medicine is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise and advanced data intelligence. This convergence is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with 3,700 people in over 50 locations globally across North America, Europe and Asia-Pacific. For more information, visit PrecisionForMedicine.com. ContactBrad EpsteinBrad.Epstein@PrecisionMedicineGrp.com
A12 藝術空間
Health Care/Hospital
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
